NIPH Clinical Trials Search

Teneligliptin effects on DPP-4 and glucagon concentrations in the serum during a meal test in patients with type 2 diabetes

Basic Information

Recruitment status	Recruiting
Health condition(s) or Problem(s) studied	Type 2 diabetes
Date of first enrollment	2013/11/01
Target sample size	20
Countries of recruitment	Japan
Study type	Interventional
Intervention(s)	Teneligliptin 20 mg/day

Outcome(s)

Primary Outcome	Postprandial serum soluble CD26/DPP-4 levels, DPP-4 activity, and plasma glucose
Secondary Outcome

Key inclusion & exclusion criteria

Age minimum	20years-old
Age maximum	Not applicable
Gender	Male and Female
Include criteria	1. Patients who give written informed consent. 2.Outpatients 3.Patients who are on dieting and exercise therapy more than 12 weeks. 4.Patients whose HbA1c between 6.9% and 10.4%. 5.Difference in HbA1c between the starting day and last visit (4 weeks ago). 6. Patients with no history of receiving DPP-4 inhibitors. 7.Patients with FPG less than 180 mg/dl and HOMA-IR more than 2.0
Exclude criteria	1.Patients who have type 1 diabetes and/or secondary diabetes (Cushing syndrome or acromegaly). 2.Contraindication for DPP-4 inhibitors 3.Patients who have heart failure (NYHA category 3-4) 4.Patients who are prone to QT prolongation. 5 Alcohol intake excess. 6.Patients who are pregnant or may be pregnant 7.History of myocardial infarction 8.Patients who have received GLP-1 receptor agonists